Published on 28 Dec 2022 on Zacks via Yahoo Finance
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
Glaukos Corporation GKOS is well-poised for growth in the coming quarters, courtesy of its favorable clinical-trial results. Solid performance in the third quarter of 2022 and continued strength in its flagship iStent also buoy optimism. Headwinds resulting from stiff competition and vendor uncertainty are major downsides.
Over the past year, the Zacks Rank #3 (Hold) stock has lost 11.3% compared with the 30.2% decline of the industry and 21.6% fall of the S&P 500.
The renowned ophthalmic medical technology and pharmaceutical company has a market capitalization of $1.95 billion. Glaukos projects 11.2% growth for 2023 and expects to witness continued improvements in its business.